Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

519
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
519
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

441
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
441
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.5K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Piperacillin-tazobactam tolerability in patients with a labeled penicillin allergy (PIPPEN).

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Gifts, Blind Spots, and Gray: Canadian Student Pharmacists' Perceptions of Pharmaceutical Industry Interactions.

American journal of pharmaceutical education·2026
Same author

Drug Coverage Policy and Legacy Prescribing: A Cross-Sectional Analysis in British Columbia.

Health science reports·2026
Same author

Sustainability pharmacy assistants in large urban hospital system.

The International journal of pharmacy practice·2026
Same author

Rising Escitalopram Use in British Columbia: Is it Rational and Evidence-Informed?

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2025
Same author

Pharmacotherapy for hypertension in adults 60 years or older.

The Cochrane database of systematic reviews·2025

Related Experiment Video

Updated: Mar 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

Eplerenone for hypertension.

Tina Sc Tam1, May Hy Wu2, Sarah C Masson3

  • 1Pharmacy, Lower Mainland Pharmacy Services, Vancouver, BC, Canada.

The Cochrane Database of Systematic Reviews
|March 1, 2017
PubMed
Summary
This summary is machine-generated.

Eplerenone effectively lowers systolic and diastolic blood pressure in patients with primary hypertension. However, evidence is insufficient to determine its impact on mortality or morbidity, and data on side effects is limited.

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

816
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.7K

Related Experiment Videos

Last Updated: Mar 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

816
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.7K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Eplerenone is an aldosterone receptor antagonist used for heart failure and hypertension.
  • Its clinical impact on cardiovascular outcomes and blood pressure reduction in hypertension requires evaluation.

Purpose of the Study:

  • To assess the effects of eplerenone monotherapy versus placebo in adults with primary hypertension.
  • Key outcomes included mortality, cardiovascular and cerebrovascular events, adverse events, and blood pressure changes.

Main Methods:

  • A systematic review and meta-analysis of randomized placebo-controlled trials.
  • Searched multiple databases (Cochrane Hypertension, CENTRAL, MEDLINE, Embase) up to March 2016.
  • Included studies focused on adult primary hypertension, excluding secondary hypertension or multiple antihypertensives.

Main Results:

  • Five trials with 1437 participants were analyzed, with treatment durations of 8-16 weeks.
  • Eplerenone (50-200 mg/day) significantly reduced systolic blood pressure by 9.21 mmHg and diastolic blood pressure by 4.18 mmHg compared to placebo.
  • No significant difference in adverse events or withdrawals was observed, but reporting was limited.

Conclusions:

  • Eplerenone effectively lowers blood pressure in primary hypertension at doses of 50-200 mg/day.
  • Evidence is insufficient to assess eplerenone's effects on mortality, morbidity, or long-term safety in hypertensive patients.
  • Further high-quality research is needed to evaluate clinical outcomes and side effects.